Palobiofarma S.L.: Corporate & Clinical Pipeline Overview
Company Overview
Palobiofarma S.L. is a clinical-stage biopharmaceutical enterprise headquartered in Spain (operating out of Pamplona and TecnoCampos Mataró). Established in 2006 by a team of drug discovery scientists, the company focuses on the discovery, design, and clinical development of first-in-class small-molecule therapeutics.
Palobiofarma's core mission is centered on modulating adenosine receptors (A1, A2A, A2B, and A3) and key enzymatic pathways (such as Phosphodiesterase 10 / PDE10) to address unmet medical needs across oncology, autoimmune disorders, respiratory conditions, gastrointestinal pathologies, and rare genetic diseases.
Continue…
Core Operations & Scientific Methodology
Palobiofarma operates via an asset-centric discovery model, maintaining internal technical expertise while utilizing strategic partnerships for late-stage research execution.
Internal Capabilities
- Virtual Drug Design & Computational Chemistry: In-silico modeling for targeting specific GPCR (G-protein coupled receptor) sites.
- Medicinal Chemistry: Optimization of small-molecule drug candidates for high selectivity and bioavailability.
- In Vitro Pharmacology: Characterization of adenosine receptor binding affinity, receptor kinetics, and pathway inhibition.
- Physicochemical Characterization & IP Generation: Early lead candidate profiling and global patent portfolio management.
External Collaborative Operations
- Non-clinical safety, toxicology, animal models, and clinical trial operations (Phase I through Phase III) are managed via Contract Research Organizations (CROs), academic research centers, and hospital networks.
Clinical Development Pipeline & Products
Palobiofarma does not commercialize off-the-shelf consumer services or general laboratory supplies; its output consists of proprietary clinical-stage drug candidates.
